BioSpace News Archive

There are more than 134,000 respiratory therapists in the U.S. Respiratory therapists work closely as part of medical teams to evaluate, treat and care for patients with breathing or other cardiopulmonary disorders.

Transaction Bolsters Carlisle’s Presence in Attractive Medical Device Segment

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

The market will accelerate at a CAGR of over 8% between 2019-2023

This session provides an overview of emerging tools for improving drug candidate selection and drug product optimization, including the application of computational tools in model informed drug development.

Aradigm Corporation announced that following a recent Oral Explanation, it has received feedback that a negative opinion is likely to be received in November 2019 from the CHMP, a committee of the European Medicines Agency, for the centralized marketing authorization application for Linhaliq as a treatment for non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa

FDA approval of TRIKAFTA, the highly effective and highly anticipated triple-combination CFTR modulator, marks the start of a new era in cystic fibrosis.

Verseau’s lead product targets PSGL-1 (P-selectin glycoprotein ligand-1), which is an adhesion molecule involved in immune cell trafficking in response to tissue injury or inflammation, according to the company.

Tucatinib is an oral tyrosine kinase inhibitor that is highly selective for HER2 without significantly inhibiting EGFR.

Thanks to a new regulatory win, AstraZeneca’s Farxiga can now be used to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with cardiovascular disease and with certain risk factors.